Sees 2026 Organic Revenue Growth of 2%-3%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy SOLV?
Sees 2026 organic revenue growth 2%-3% from $8.33B in 2025, consensus $8.02B.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SOLV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SOLV
Wall Street analysts forecast SOLV stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 74.200
Low
79.00
Averages
93.71
High
105.00
Current: 74.200
Low
79.00
Averages
93.71
High
105.00
About SOLV
Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SOLVENTUM CORP: UBS Increases Target Price from $79 to $82
- Company Update: UBS has raised the target price for Solventum Corp.
- New Target Price: The new target price is set at $82, up from the previous $79.
See More
Solventum Shares Decline Despite Surpassing Wall Street Earnings Expectations
- Stock Performance: Shares of healthcare supplier Solventum experienced a decline early Friday.
- Earnings Report: The company reported strong fourth-quarter earnings and provided guidance for 2026.
See More
Solventum Corporation Q4 2025 Earnings Call Highlights
- Significant Sales Growth: Solventum reported $2 billion in sales for Q4 2025, reflecting a 3.5% increase year-over-year, despite a 3.7% decline on a reported basis due to the impact of the P&F divestiture and Acera acquisition, demonstrating the company's resilience and growth potential in the market.
- Strategic Acquisition Progress: The acquisition of Acera Surgical positions Solventum in the fast-growing synthetic tissue market, expected to contribute meaningfully to future sales growth while optimizing the existing technology portfolio and enhancing competitive positioning.
- Share Repurchase Program: Solventum announced a $1 billion share repurchase program set to begin in January 2026, aimed at achieving a more balanced capital structure, reflecting management's confidence in the company's future value.
- Optimistic Future Outlook: The company guided for organic sales growth of 2% to 3% in 2026, with operating margins projected to rise to 21% to 21.5%, indicating ongoing improvements in sales leverage and supply chain efficiencies.
See More
Solventum Corporation Q4 Earnings Beat Expectations
- Earnings Beat: Solventum Corporation reported a Q4 non-GAAP EPS of $1.57, exceeding expectations by $0.07, which reflects the company's robust profitability and may enhance investor confidence.
- Revenue Decline: The company generated $2 billion in revenue for Q4, a 3.4% year-over-year decline, yet it surpassed expectations by $40 million, indicating a relatively stable market performance amidst challenges.
- Self-Help Program Progress: Solventum's self-help initiatives are ahead of schedule, and despite negative market sentiment, the company's commitment to achieving long-term growth targets could lay a solid foundation for future performance.
- Analyst Upgrade: KeyBanc has upgraded Solventum's rating, reflecting growing recognition of the company's long-term growth potential, which may attract increased investor interest.
See More
Solventum Corporation Reports Increased Q4 Profit
- Profit Growth: Solventum Corporation reported a fourth-quarter net profit of $63 million, translating to $0.36 per share, which is a significant increase from last year's $30 million and $0.17, indicating improved profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $277 million or $1.57 per share, showcasing strong performance in core operations despite a decline in overall revenue.
- Revenue Decline: The company's revenue for the fourth quarter fell to $1.99 billion, a 3.9% decrease from $2.07 billion last year, reflecting challenges in the market environment and competitive pressures.
- Market Reaction: Despite the revenue decline, the profit growth may boost investor confidence, likely leading to a positive impact on the company's future stock performance.
See More
Stock Market Movers: Nvidia, Sandisk, Salesforce, C3.ai, IonQ, Nutanix, and Others
- Stock Market Trends: Stock futures were declining on Thursday, indicating a downturn in the market.
- Nvidia's Earnings Impact: Nvidia's strong fourth-quarter earnings report was not enough to maintain the recent rebound in the tech sector.
See More
SOLVENTUM CORP: UBS Increases Target Price from $79 to $82
- Company Update: UBS has raised the target price for Solventum Corp.
- New Target Price: The new target price is set at $82, up from the previous $79.
See More
Solventum Shares Decline Despite Surpassing Wall Street Earnings Expectations
- Stock Performance: Shares of healthcare supplier Solventum experienced a decline early Friday.
- Earnings Report: The company reported strong fourth-quarter earnings and provided guidance for 2026.
See More
Solventum Corporation Q4 2025 Earnings Call Highlights
- Significant Sales Growth: Solventum reported $2 billion in sales for Q4 2025, reflecting a 3.5% increase year-over-year, despite a 3.7% decline on a reported basis due to the impact of the P&F divestiture and Acera acquisition, demonstrating the company's resilience and growth potential in the market.
- Strategic Acquisition Progress: The acquisition of Acera Surgical positions Solventum in the fast-growing synthetic tissue market, expected to contribute meaningfully to future sales growth while optimizing the existing technology portfolio and enhancing competitive positioning.
- Share Repurchase Program: Solventum announced a $1 billion share repurchase program set to begin in January 2026, aimed at achieving a more balanced capital structure, reflecting management's confidence in the company's future value.
- Optimistic Future Outlook: The company guided for organic sales growth of 2% to 3% in 2026, with operating margins projected to rise to 21% to 21.5%, indicating ongoing improvements in sales leverage and supply chain efficiencies.
See More
Solventum Corporation Q4 Earnings Beat Expectations
- Earnings Beat: Solventum Corporation reported a Q4 non-GAAP EPS of $1.57, exceeding expectations by $0.07, which reflects the company's robust profitability and may enhance investor confidence.
- Revenue Decline: The company generated $2 billion in revenue for Q4, a 3.4% year-over-year decline, yet it surpassed expectations by $40 million, indicating a relatively stable market performance amidst challenges.
- Self-Help Program Progress: Solventum's self-help initiatives are ahead of schedule, and despite negative market sentiment, the company's commitment to achieving long-term growth targets could lay a solid foundation for future performance.
- Analyst Upgrade: KeyBanc has upgraded Solventum's rating, reflecting growing recognition of the company's long-term growth potential, which may attract increased investor interest.
See More
Solventum Corporation Reports Increased Q4 Profit
- Profit Growth: Solventum Corporation reported a fourth-quarter net profit of $63 million, translating to $0.36 per share, which is a significant increase from last year's $30 million and $0.17, indicating improved profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $277 million or $1.57 per share, showcasing strong performance in core operations despite a decline in overall revenue.
- Revenue Decline: The company's revenue for the fourth quarter fell to $1.99 billion, a 3.9% decrease from $2.07 billion last year, reflecting challenges in the market environment and competitive pressures.
- Market Reaction: Despite the revenue decline, the profit growth may boost investor confidence, likely leading to a positive impact on the company's future stock performance.
See More
Stock Market Movers: Nvidia, Sandisk, Salesforce, C3.ai, IonQ, Nutanix, and Others
- Stock Market Trends: Stock futures were declining on Thursday, indicating a downturn in the market.
- Nvidia's Earnings Impact: Nvidia's strong fourth-quarter earnings report was not enough to maintain the recent rebound in the tech sector.
See More
